Category: Pharma, Life Sciences & Med Tech Players
-
Novo Nordisk signs GLP-1 licensing agreement with China’s Hengrui Pharma
Novo Nordisk and Hengrui Pharma’s agreement, subject to antitrust approval, will allow Novo to obtain exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macao, and Taiwan.
-
Mylan seeks declaratory judgment against Novo Nordisk over newly issued Wegovy patent, aiming to preempt a new Delaware lawsuit
Mylan has asked a Delaware court to declare a newly issued Novo Nordisk Wegovy patent invalid and not infringed, opening a new front in their long-running Hatch-Waxman fight over generic semaglutide.
-
Federal court dismisses Entresto antitrust suit against Novartis: patent listing in Orange Book was proper
Judge Liman held that the U.S. Patent No. 8,101,659 claims the active ingredients on Entresto’s FDA label, so its Orange Book listing was proper, ending a payor’s antitrust case with prejudice.
-
Daiichi Sankyo loses six CNIPA administrative patent-linkage cases over mirogabalin formulation patentsÂ
Daiichi Sankyo has now lost six Chinese patent-linkage cases over generic mirogabalin after the CNIPA found two dosage strengths outside three formulation patents. The rulings show the growing importance of CNIPA’s administrative route for resolving patent disputes before generic launch.
-
Abbott wins another UPC PI against glucose sensor rival Sibio
The UPC’s Milan Local Division has granted Abbott a second UPC-wide preliminary injunction in its patent infringement case against Chinese rival Sibio, despite allowing the latter’s late-presented claim construction arguments to be admitted.
-
Accord slapped with injunction in Munich after invalidity losses in EPO, German Federal Patent CourtÂ
The Munich I Regional Court has found that Accord infringed TOWA’s dabigatran etexilate patent, issuing an injunction against the company. Dabigatran etexilate is an oral anticoagulant medicine that stops blood clots from forming, preventing strokes, deep vein thrombosis, and pulmonary embolism, among other things.
-
Lupin granted win against Vertex in Delaware over cystic fibrosis drug patents
Lupin’s generic version of Vertex’s cystic fibrosis treatment Kalydeco does not infringe the latter’s patents, Judge Stephanos Bibas of the Third Circuit has ruled.
-
FTC urges Fourth Circuit to reject Amgen plea to shield Roche patent acquisition: deal “threatens to upend” long-settled antitrust framework
The U.S. Federal Trade Commission has filed an amicus brief in an antitrust case between CareFirst and Amgen, urging the Fourth Circuit to reject Amgen’s bid to shield its acquisition of pending patent applications from antitrust scrutiny, as such procurements violate the Sherman Act and are not immunized by the Noerr-Pennington doctrine.
-
UPC Court of Appeal upholds Abbott’s glucose sensor patent: rejects Sibio’s added matter, inventive step attacks
The UPC Court of Appeal has dismissed Sibio’s bid to revoke Abbott’s continuous glucose monitor patent, confirming its own earlier finding from a related injunction case and issuing two headnotes that will guide how the court treats omitted features in future added matter disputes.
-
China’s top court overturns Nefecon generic PI despite U.S. Paragraph III-style no-launch pledgeÂ
A Chinese generic of Nefecon obtained formal approval after promising not to launch until patent expiry, then used that approval to seek procurement listings. China’s top court nevertheless held that the broken Paragraph III-style pledge was a regulatory breach – not an admission of patent infringement.